| Literature DB >> 33372611 |
Wei Zhong Zhu1, Aaron Olson1,2, Michael Portman1,2, Dolena Ledee3,4.
Abstract
BACKGROUND: Sex and age have substantial influence on thyroid function. Sex influences the risk and clinical expression of thyroid disorders (TDs), with age a proposed trigger for the development of TDs. Cardiac function is affected by thyroid hormone levels with gender differences. Accordingly, we investigated the proteomic changes involved in sex based cardiac responses to thyroid dysfunction in elderly mice.Entities:
Keywords: Aged; Heart; Proteomics; Sex-based; Thyroid hormone
Year: 2020 PMID: 33372611 PMCID: PMC7722307 DOI: 10.1186/s12953-020-00167-3
Source DB: PubMed Journal: Proteome Sci ISSN: 1477-5956 Impact factor: 2.480
Fig. 1Serum T4 concentrations in aged male (M) and female (F) mice. PTU - hypothyroid mice, CON - control mice, TH - hyperthyroid mice, PRE – samples before treatment, and POST – samples after treatment. Data are presented as mean ± SEM, n = 6 animals/sex/treatment, two-way ANOVA followed by Tukey post hoc analysis
A. Echocardiographic and B. Morphometric analysis of the left ventricle after four weeks on prescribed diet and morphometric measurements
| A | Baseline M CON | Final M CON | Baseline M PTU | Final M PTU | Baseline M TH | Final M TH | Baseline F CON | Final F CON | Baseline F PTU | Final F PTU | Baseline F TH | Final F TH |
| EDD, mm | 3.9±0.1 | 4.1±0.1 | 4.3±0.07 | 4.1±0.1 | 4.0±0.2 | 4.4±0.09 | 4.0±0.07 | 3.9±0.07 | 3.9±0.09 | 4.0±0.06 | 3.8±0.1 | 4.0±0.08 |
| ESD, mm | 2.8±0.2 | 3.1±0.1 | 3.3±0.09 | 3.2±0.1 | 3.0±0.2 | 3.3±0.1 | 3.0±0.1 | 3.0±0.08 | 2.9±0.1 | 3.1±0.07 | 2.8±0.2 | 2.8±0.09 |
| EF, % | 50±3.6 | 47±3.4 | 48±2 | 46±2 | 53±3.7 | 48±2.6 | 49±3 | 45±2 | 49±2.4 | 45±2.7 | 54±3.7 | 57±2.1 |
| FS, % | 25±2.2 | 24±2.1 | 24±1 | 22±.9 | 27±2.4 | 25±1.5 | 24±2 | 22±1.2 | 25±1.5 | 22±1.6 | 28±2.4 | 30±1.4 |
| LVPWd, mm | 0.81±.03 | 0.9±0.05 | 0.86±0.04 | 0.78±0.04 | 0.89±0.03 | 0.88±0.05 | 0.96±-.04 | 0.93±0.07 | 0.81±0.06 | 0.9±0.07 | ||
| HR, BPM | 480±18 | 498±23 | 455±17 | 482±21 | 474±18 | 514±11 | 471±15 | 417±17 | 504±17 | |||
| B | Baseline M CON | Final M CON | Baseline M PTU | Final M PTU | Baseline M TH | Final M TH | Baseline F CON | Final F CON | Baseline F PTU | Final F PTU | Baseline F TH | Final F TH |
| BW, g | 35±0.7 | 35±0.8 | 35±0.9 | 34±0.9 | 33±0.6 | 29±0.6 | 30±1 | 26±0.7 | 25±0.3 | 26±0.7 | ||
| HW, mg | n/a | 169±9 | n/a | n/a | n/a | 146±4 | n/a | n/a | ||||
| HW/TL (mg/mm) | n/a | 9.7±0.6 | n/a | n/a | n/a | 8.3±0.2 | n/a | n/a | ||||
CON Euthyroid, PTU Hypothyroid, TH Hyperthyroid, EDD left ventricular end diastolic diameter, ESD left ventricular end systolic diameter, FS left ventricular percent fractional shortening, EF left ventricular percent ejection fraction, LVPWd left ventricular posterior wall end diastole, HR heart rate, BPM beats per minute, BW body weight, HW heart weight, TL tibia length. Values are means ± SEM. N = # of animals/sex/treatment. Bolded numbers represent significant changes. Two way ANOVA followed by Tukey post hoc analysis performed on the serial values from the same animals for EDD, ESD, EF, FS, LWPWD, HR and body weight, *p < 0.05, **p < 0.005; one-way ANOVA followed by Tukey post hoc analysis performed on HW and HW/TL values comparing treated group to same sex control, #p < 0.05, ##p < 0.005
Fig. 2Representative images of 2D-DIGE scanned for Cy3 and Cy5 labeled proteins using Typhoon Scanner and overlaid for detection of changes in protein abundance. MCON, male control and MTH, male hyperthyroid
Protein Ratio of identified proteins between specified groups
FTH female hyperthyroid, FCON female control, FPTU female hypothyroid, MTH male hyperthyroid, MCON male control, MPTU male hypothyroid. Colored cells with ≥1.5-fold difference and p-value ≤0.1, n = 3 animals/sex/group
Enriched gene ontology (GO) terms for molecular function and KEGG pathway of identified proteins
| Category | Term | Fold Enrichment | Bonferroni | Benjamini | FDR | |
|---|---|---|---|---|---|---|
| Molecular Function | GO:0051287~NAD binding | 35.91 | 6.00E-07 | 1.09E-04 | 1.09E-04 | 7.41E-04 |
| GO:0016491~oxidoreductase activity | 6.54 | 1.30E-06 | 2.36E-04 | 1.18E-04 | 1.60E-03 | |
| GO:0016616~oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 41.15 | 1.17E-04 | 0.02 | 0.01 | 0.14 | |
| GO:0008137~NADH dehydrogenase (ubiquinone) activity | 37.62 | 1.53E-04 | 0.03 | 0.01 | 0.19 | |
| GO:0051539~4 iron, 4 sulfur cluster binding | 32.92 | 2.28E-04 | 0.04 | 0.01 | 0.28 | |
| GO:0003954~NADH dehydrogenase activity | 75.96 | 6.66E-04 | 0.11 | 0.02 | 0.82 | |
| GO:0051536~iron-sulfur cluster binding | 20.57 | 9.15E-04 | 0.15 | 0.02 | 1.12 | |
| GO:0008092~cytoskeletal protein binding | 19.36 | 0.001 | 0.18 | 0.02 | 1.34 | |
| GO:0000287~magnesium ion binding | 8.15 | 0.003 | 0.43 | 0.05 | 3.71 | |
| GO:0050839~cell adhesion molecule binding | 13.91 | 0.02 | 0.97 | 0.21 | 21.07 | |
| GO:0019899~enzyme binding | 4.29 | 0.03 | 0.99 | 0.26 | 28.94 | |
| KEGG Pathway | mmu01100:Metabolic pathways | 3.46 | 8.21E-09 | 4.93E-07 | 4.93E-07 | 8.23E-06 |
| mmu01130:Biosynthesis of antibiotics | 10.27 | 9.09E-09 | 5.46E-07 | 2.73E-07 | 9.11E-06 | |
| mmu05012:Parkinson's disease | 11.06 | 9.14E-07 | 5.49E-05 | 1.83E-05 | 9.16E-04 | |
| mmu00190:Oxidative phosphorylation | 10.54 | 7.29E-06 | 4.37E-04 | 1.09E-04 | 7.30E-03 | |
| mmu05010:Alzheimer's disease | 8.28 | 3.52E-05 | 2.11E-03 | 4.23E-04 | 3.53E-02 | |
| mmu05016:Huntington's disease | 7.43 | 7.04E-05 | 0.004 | 0.001 | 0.07 | |
| mmu01200:Carbon metabolism | 9.51 | 3.42E-04 | 0.02 | 0.00 | 0.34 | |
| mmu00020:Citrate cycle (TCA cycle) | 22.98 | 6.20E-04 | 0.04 | 0.00 | 0.62 | |
| mmu04932:Non-alcoholic fatty liver disease (NAFLD) | 7.02 | 0.001 | 0.08 | 0.01 | 1.35 | |
| mmu01210:2-Oxocarboxylic acid metabolism | 29.02 | 0.004 | 0.23 | 0.03 | 4.37 | |
| mmu04610:Complement and coagulation cascades | 9.67 | 0.01 | 0.36 | 0.04 | 7.24 | |
| mmu04260:Cardiac muscle contraction | 9.55 | 0.01 | 0.37 | 0.04 | 7.50 | |
| mmu01230:Biosynthesis of amino acids | 9.43 | 0.01 | 0.38 | 0.04 | 7.76 |
Fig. 3A protein-protein interaction network among the 55 identified proteins. The line thickness represents the supported confidence (correlation coefficient) between nodes. Proteins bolded and underlined possess potential THR binding sites
Fig. 4Representative 2D-DIGE and western blots of A1BG and ACAA2. a female A1BG, b male A1BG, c female ACAA2, and d male ACAA2. Top panels show the 2D-DIGE images comparing euthyroid (CON) to hypothyroid (PTU) and hyperthyroid (TH). Right-lower panel immunoblots showing protein abundance between groups. Whisker plots graph the immunoblot signal intensities presented as mean ± SEM. Statistics - one-way ANOVA followed by Tukey post hoc analysis (n = 4 animals/sex/treatment)
Fig. 5Representative western blots of expression profiles for total A1BG and ACAA2 comparing male (M) and female (F) CON, PTU and TH groups. PTU – hypothyroid, TH – hyperthyroid, and CON – euthyroid. Whisker plots of data are presented as mean ± SEM, n = 4 animals/sex/treatment, two-way ANOVA followed by Tukey post hoc analysis